Adma Biologics (ADMA) Income from Continuing Operations (2011 - 2025)
Adma Biologics (ADMA) reported Income from Continuing Operations of 49379000.0 for Q4 2025, down 55.87% on a YoY basis from 111896000.0 in Q4 2024, and up 35.55% quarter-over-quarter from 36428000.0 in Q3 2025.
Adma Biologics (ADMA) Income from Continuing Operations (2011 - 2025) Analysis & Trends
Adma Biologics has reported Income from Continuing Operations for 13 years, with the latest figure at 49379000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 55.87% year-over-year to 49379000.0; the trailing twelve-month figure through Dec 2025 stood at 146930000.0 (down 25.67% YoY), and the FY2025 full-year result was 146930000.0, down 25.67% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 49379000.0, up from 36428000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 111896000.0 in Q4 2024, with the low at 18821986.0 in Q2 2021.
- Historically, Income from Continuing Operations has averaged 10730350.0 across 5 years, with a median of 1903000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 1299.96% — and 2025, when it sank 55.87%.
- Adma Biologics' Income from Continuing Operations stood at 16504574.0 in 2021, then grew by 28.55% to 11792616.0 in 2022, then jumped by 189.84% to 10594000.0 in 2023, then soared by 956.22% to 111896000.0 in 2024, then slumped by 55.87% to 49379000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 49379000.0 (Q4 2025), 36428000.0 (Q3 2025), and 34219000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn | 49.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.38 Mn |
| Sep 30, 2025 | 36.43 Mn |
| Jun 30, 2025 | 34.22 Mn |
| Mar 31, 2025 | 26.90 Mn |
| Dec 31, 2024 | 111.90 Mn |
| Sep 30, 2024 | 35.91 Mn |
| Jun 30, 2024 | 32.06 Mn |
| Mar 31, 2024 | 17.81 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 2.57 Mn |
| Jun 30, 2023 | -6.37 Mn |
| Mar 31, 2023 | -6.79 Mn |
| Dec 31, 2022 | -11.79 Mn |
| Sep 30, 2022 | -14.89 Mn |
| Jun 30, 2022 | -13.75 Mn |
| Mar 31, 2022 | -18.17 Mn |
| Dec 31, 2021 | -16.50 Mn |
| Sep 30, 2021 | -17.73 Mn |
| Jun 30, 2021 | -18.82 Mn |
| Mar 31, 2021 | -18.34 Mn |